Abbott Laboratories (ABT)
Abbott Laboratories Revenue Growth: 4.60%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ABT Revenue Growth Rankings
| Overall | 45th percentile | 2410 of 4399 |
| Sector | 37th percentile | 287 of 461 in Healthcare |
| Industry | 52nd percentile | 9 of 19 in Drug Manufacturers - Major |
ABT Revenue Growth Range, Past 5 Years
| Minimum | -0.70% | Mar 2009 |
| Maximum | 17.76% | Jun 2010 |
| Average | 10.70% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these ABT related companies
ABT News
EBR: Watchlist/worksheet/4 Trading Ideas: $FIRE $WG $ABT $ANGI http://stks.co/3vnQ
about 4 hours ago by TheEquitiesRoom
about 4 hours ago by TheEquitiesRoom
I believe $ABT will go up in the next couple of day to a second top of a double top and then go south
about 24 hours ago by john_abot
about 24 hours ago by john_abot
Price target on $ABT is 64 but I could easily see a 3% pullback to the 50 day if market volatility keeps up. Either way long-term entry.
about 5 days ago by AlphaoverBetaTrading
about 5 days ago by AlphaoverBetaTrading
$OSUR fromwith first non-prescription HIV test buyout becomes very real $JNJ $ABT $ROG very nice price here
about 6 days ago by leahcim474
about 6 days ago by leahcim474
Listen to $ABT Abbott at Deutsche Bank AG Health Care Conference - live at 10:00 AM, ondemand after - http://stks.co/3if1
about 14 days ago by earningscast
about 14 days ago by earningscast
got mixed up, I meant $ABT in trouble because they pleaded guilty to rebranding a drug http://stks.co/3iDN
about 15 days ago by epime7heus
about 15 days ago by epime7heus
@jimcramer 's $ABT in trouble. His $COG and $CELG also still terrible recomendations. Worst in my port.
about 15 days ago by epime7heus
about 15 days ago by epime7heus
$CHK Scary day in the stock market when this is my best performing stock in my portfolio today. $CHK and $ABT are my only green.
about 19 days ago by baumusc
about 19 days ago by baumusc
$ABT http://stks.co/3ZBj closed Friday on shrinking candles & near doji at RSI 70+, will see if rests or drives higher
about 24 days ago by harmongreg
about 24 days ago by harmongreg
$VVUS halt is becuase FDA pre released and co wanted AH... might not open until monday. at 28-30 plus... $PFE $ABT wants this drug and co.
about 25 days ago by selectstock
about 25 days ago by selectstock
$ABT evening star on te daily or perhaps just a pause. No positions.
about 25 days ago by indiantraveler
about 25 days ago by indiantraveler
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ABT | 62.26 | +0.45 | +0.73% | 97.19B |
| ABR | 6.15 | +0.15 | +2.50% | 144.84M |
| ABM | 21.76 | +0.09 | +0.42% | 1.156B |
| ABH | 10.44 | -0.07 | -0.67% | 1.020B |
| ABCO | 95.99 | +0.21 | +0.22% | 1.597B |
| ABC | 36.53 | +0.45 | +1.25% | 9.303B |
| ABAX | 33.10 | -0.01 | -0.03% | 718.16M |
| AB | 13.76 | -0.01 | -0.11% | 1.449B |
| AAPL | 565.97 | +4.69 | +0.84% | 523.32B |
| AAP | 69.91 | +0.09 | +0.13% | 5.092B |
